TYRU8 Apr 2014 22:58
April 01 2014, 2:50pm TyraTech is aiming for a significant market share, as competing products are long in the tooth and do not receive much marketing support.
TyraTech’s (LON:TYR) treatment for head lice has already hit shelves in over 4,000 Walmart stores in the US, the AIM-listed company has revealed.
The retail giant has stocked all of its US stores with Vamousse, which is said to be safer and more effective than traditional treatments.
Bruno Jactel, chief executive of the natural insecticide group, said: “The board is very pleased that we are currently on schedule both in terms of number of stores and timings of sales for our Vamousse head lice treatment, with products already selling in the USA.
“We are confident this roll-out will greatly raise the profile of Vamousse.”
Speaking to Proactive Investors, Jactel said the company remains in discussions with numerous other retailers interested in stocking its products, but is largely focusing on making the Wal-Mart roll-out a success at the moment.
In September of last year the company revealed it has reached a preliminary distribution agreement for 2014 to place TyraTech's head lice product with a major pharmacy chain in the USA, representing around 8,500 pharmacy stores or close to 15% of retail pharmacy stores in the USA
The company is supporting the launch of Vamousse in the US with a “very strong marketing campaign”, Jactel revealed, combining “clear information to the mums as well as to the [medical] professionals”.
“We are working in a category where the current competitors are not really investing in marketing – their products being very old, and maybe [regarded as] cash cows,” Jactel said.
TyraTech’s products are based on natural essential oils that act against pests but have no effect on humans.
Its products focus on personal care, which includes the head lice treatments, animal health and household, agricultural and garden insecticides.
Sign In
Follow the stocks
